Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells.

APOBEC-mediated cytidine deamination of HIV-1 genomes during reverse transcription has been shown to be a potent mechanism of host restriction for HIV-1 infection ex vivo and in vitro. However, this defense system can be overcome by the viral protein Vif. Unlike other mechanisms of host restriction, the APOCEC-Vif interaction leaves an imprint on integrated proviruses in the form of G-->A hypermutation. In the current work we systematically studied levels, contexts, and patterns of HIV-1 hypermutation in vivo. The analysis of 24 full-genome HIV-1 sequences retrieved from primary PBMCs, representing infections with several HIV-1 clades, and the inclusion of 7 cognate pairs of hypermutated/non-hypermutated sequences derived from the same patient sample, provided a comprehensive view of the characteristics of APOBEC-mediated restriction in vivo. Levels of hypermutation varied nearly 5-fold among the studied proviruses. GpG motifs were most frequently affected (22/24 proviruses). Levels of hypermutation varied across the genome. The reported "twin peak" pattern of hypermutation was observed in 18/24 hypermutants, but the remainder exhibited singular non-conforming patterns. These data suggest considerable complexity in the interplay of host restriction and viral defense during HIV-1 infection.

[1]  Michel Henry,et al.  APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. , 2004, Nucleic acids research.

[2]  Rongzhen Xu,et al.  STAT1-Independent Cell Type-Specific Regulation of Antiviral APOBEC3G by IFN-α1 , 2006, The Journal of Immunology.

[3]  D. Burke,et al.  Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. , 1995, Virology.

[4]  R. König,et al.  Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome , 2004, Nature Structural &Molecular Biology.

[5]  M. Alary,et al.  APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians , 2006, AIDS.

[6]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[7]  W. Greene,et al.  Newly Synthesized APOBEC3G Is Incorporated into HIV Virions, Inhibited by HIV RNA, and Subsequently Activated by RNase H , 2007, PLoS pathogens.

[8]  S. Heath,et al.  Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. , 2005, The Journal of infectious diseases.

[9]  Xiao-Fang Yu,et al.  Cell-specific regulation of APOBEC3F by interferons. , 2007, Acta biochimica et biophysica Sinica.

[10]  Hulin Wu,et al.  APOBEC3G levels predict rates of progression to AIDS , 2007, Retrovirology.

[11]  M Sala,et al.  G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Luban,et al.  Cyclophilin A regulates HIV‐1 infectivity, as demonstrated by gene targeting in human T cells , 2001, The EMBO journal.

[13]  Svend K. Petersen-Mahrt,et al.  The nuclear DNA deaminase AID functions distributively whereas cytoplasmic APOBEC3G has a processive mode of action. , 2007, DNA repair.

[14]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[15]  G. Pantaleo,et al.  Immunopathogenesis of HIV infection. , 1998, AIDS research and human retroviruses.

[16]  Jianbo Chen,et al.  Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. , 2007, Virology.

[17]  David Nolan,et al.  Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation , 2007, Journal of Virology.

[18]  J. Mascola,et al.  Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel. , 2005, AIDS research and human retroviruses.

[19]  A. Meyerhans,et al.  Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes , 1991, Journal of virology.

[20]  Takeshi Kurosu,et al.  Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication , 2004, Journal of Virology.

[21]  U. Alam,et al.  Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants , 2002, AIDS.

[22]  W. Greene,et al.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.

[23]  Patrick T. Dolan,et al.  Biochemical Differentiation of APOBEC3F and APOBEC3G Proteins Associated with HIV-1 Life Cycle* , 2007, Journal of Biological Chemistry.

[24]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[25]  M. Hoelscher,et al.  HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania , 2005, AIDS.

[26]  W. Greene,et al.  Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation , 2006, The Journal of experimental medicine.

[27]  S. Wain-Hobson,et al.  Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication , 2006, Nucleic acids research.

[28]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[29]  M. Malim,et al.  Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins , 2004, Current Biology.

[30]  A. Gronenborn,et al.  Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G , 2007, Nucleic acids research.

[31]  E. Sanders-Buell,et al.  HyperPack: a software package for the study of levels, contexts, and patterns of APOBEC-mediated hypermutation in HIV. , 2007, AIDS research and human retroviruses.

[32]  D. Ho,et al.  Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.

[33]  S. Wahl,et al.  Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti–HIV-1 activity , 2006, The Journal of experimental medicine.

[34]  J. Carr,et al.  Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping. , 2006, AIDS research and human retroviruses.

[35]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[36]  S. Wain-Hobson,et al.  Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  F. Clavel,et al.  Hypermutation of HIV-1 DNA in the Absence of the Vif Protein , 2003, Science.

[38]  Tracy L. Diamond,et al.  Identification of a Simian Immunodeficiency Virus Reverse Transcriptase Variant with Enhanced Replicational Fidelity in the Late Stage of Viral Infection* , 2001, The Journal of Biological Chemistry.

[39]  F. McCutchan,et al.  Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells , 2001, Journal of Virology.

[40]  M. E. Harris,et al.  A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. , 2003, AIDS research and human retroviruses.

[41]  V. Pathak,et al.  Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Berkhout,et al.  The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. , 1994, Nucleic acids research.

[43]  M. Hoelscher,et al.  HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. , 2004, AIDS research and human retroviruses.

[44]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[45]  Jeremy MG Taylor,et al.  Resistance to HIV‐1 Infection , 1994 .

[46]  J. Carr,et al.  Characterization of subtype A HIV-1 from Africa by full genome sequencing. , 1999, AIDS.

[47]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[48]  J. Fitzgibbon,et al.  A new type of G-->A hypermutation affecting human immunodeficiency virus. , 1993, AIDS research and human retroviruses.

[49]  M. Khan,et al.  Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.

[50]  W. Greene,et al.  Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells* , 2006, Journal of Biological Chemistry.

[51]  Reuben S Harris,et al.  Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. , 2004, Journal of molecular biology.

[52]  Cynthia Ludwig,et al.  Gastrointestinal tract , 2005, The American Journal of Digestive Diseases.

[53]  B. Strack,et al.  Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.

[54]  Reuben S. Harris,et al.  Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.

[55]  L. Kleiman,et al.  APOBEC3G Inhibits DNA Strand Transfer during HIV-1 Reverse Transcription* , 2007, Journal of Biological Chemistry.

[56]  R. Reichman,et al.  APOBEC3G/CEM15 (hA3G) mRNA Levels Associate Inversely with Human Immunodeficiency Virus Viremia , 2005, Journal of Virology.

[57]  W. Brown,et al.  APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo , 2004, Current Biology.

[58]  D. Burke,et al.  Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. , 1995, AIDS research and human retroviruses.

[59]  Noah Kiwanuka,et al.  Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. , 2002, AIDS research and human retroviruses.

[60]  J. Overbaugh,et al.  Lentiviral genomes with G-to-A hypermutation may result from Taq polymerase errors during polymerase chain reaction. , 1996, AIDS research and human retroviruses.

[61]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[62]  S. Goff.  Retrovirus restriction factors. , 2004, Molecular cell.

[63]  P. T. N. Sarkis,et al.  7SL RNA Mediates Virion Packaging of the Antiviral Cytidine Deaminase APOBEC3G , 2007, Journal of Virology.

[64]  M. Marin,et al.  Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. , 2005, AIDS research and human retroviruses.

[65]  M. Goodman,et al.  APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA , 2006, Nature Structural &Molecular Biology.

[66]  M. Robb,et al.  The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. , 2004, AIDS Research and Human Retroviruses.

[67]  Amalio Telenti,et al.  APOBEC3G Genetic Variants and Their Influence on the Progression to AIDS , 2004, Journal of Virology.